ICON (ICLR) vs iSpecimen (ISPC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
ICON is the larger company by market cap ($12.32 billion vs $2.8 million), about 4406.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | ICLR | ISPC |
|---|---|---|
| Share price | $159.68 | $1.11 |
| Market cap | $12.32B | $2.80M |
| 1-day change | -2.68% | +0.92% |
| YTD return | -9.95% | — |
| 1-year return | -12.09% | — |
| 5-year return | -40.34% | — |
| P/E ratio (TTM) | 168.08 | — |
| Forward P/E | 13.51 | — |
| EPS (TTM) | $0.95 | $-52.98 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $8.25B | — |
| Revenue growth (YoY) | +0.76% | — |
| Net income (latest FY) | $229.34M | — |
| Gross margin | 26.37% | — |
| Operating margin | 5.37% | — |
| Net margin | 2.78% | — |
| 52-week high | $203.91 | $40.04 |
| 52-week low | $66.57 | $1.02 |
| Distance from 52-week high | -21.69% | -97.23% |
| Analyst consensus | buy | — |
| Avg. price target upside | +15.49% | — |
| Average volume | 814.74K | 671.33K |
| Shares outstanding | 77.15M | 2.52M |
| Employees | 40,200 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ICON is about 4406.5 times larger than iSpecimen by market value ($12.32B vs $2.80M).
About ICON
ICLR stock →ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 40,200 employees
ICLR vs ISPC FAQ
Which is bigger, ICON or iSpecimen?
ICON (ICLR) is larger, with a market capitalization of $12.32B compared with $2.80M for iSpecimen (ISPC).
Are ICON and iSpecimen in the same industry?
Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.